Italia markets close in 3 hours 10 minutes

FTSE MIB
33.747,52
+593,47(+1,79%)
Dow Jones
39.118,86
-45,24(-0,12%)
Nasdaq
17.732,60
-126,10(-0,71%)
Nikkei 225
39.631,06
+47,98(+0,12%)
Petrolio
82,05
+0,51(+0,63%)
Bitcoin EUR
58.286,89
+1.048,89(+1,83%)

ABBV Jan 2025 260.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,1200

0,0000

(0,00%)

In data: 01:06PM EDT. Mercato aperto.

GlobeNewswire
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Data readout expected in Q4 2024SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Data from the trial are expected in the fourth quarter of 2024. AL00